Akari Therapeutics’ Phase II trial investigating Coversin (nomacopan) in mild-to-moderate bullous pemphigoid has...
Trial finds depression drug sertraline reduces anxiety first
A new clinical trial led by University College London (UCL) has found that common antidepressant sertraline causes a decrease in anxiety weeks before relieving depressive symptoms.
Could PF-06480605 Phase IIb trial registration pave the way for Pfizer’s dominance in UC space?
Pfizer's PF-06480605 is an antibody that blocks tumour necrosis factor.
Pfizer’s Phase II results strengthen likely regulatory approval for 20vPnC
Pfizer announced positive results for a Phase II study following administration of three doses in a four-dose series to assess the safety and immunogenicity of 20vPnC.
Psilocybin depression therapy faces cost-effectiveness challenges versus J&J’s Spravato
Companies researching psilocybin therapy have ongoing Phase II or III clinical trials, but will need to optimise the treatment paradigm to streamline costs, experts said.
Novartis pushes back regulatory filing of Rett syndrome gene therapy
Novartis completed its acquisition of AveXis in May 2018 for $8.7bn and successfully brought AveXis’ most advanced asset, Zolgensma past FDA approval on May 2019 for spinal muscular atrophy.
Earlier treatment with Ocrevus reduces permanent disability progression by 42% in MS
Roche's Ocrevus has become the MS market leader in its class since its approval in 2017.
Spruce’s rare disease drug yields positive data in Phase IIa trial
Spruce Biosciences has reported positive data from a Phase IIa clinical trial of tildacerfont to treat patients with congenital adrenal hyperplasia (CAH).
bluebird bio reports new data for Lenti-D gene therapy
Biotechnology firm bluebird bio has reported positive long-term follow-up data from the Phase II/III Starbeam clinical trial of Lenti-D gene therapy in treating cerebral adrenoleukodystrophy (CALD).
Movantik for the Treatment of Opioid-Induced Constipation
Movantik™ (naloxegol) is an opioid antagonist therapy indicated for the treatment of opioid-induced constipation in adult patients with chronic, non-cancerous pain.
New positive data presented for Janssen’s ponesimod remains questionable
According to GlobalData, ponesimod is expected to be launched in the US in 2020 and it will become the third-in-class S1P receptor modulator behind Gilenya (fingolimod) and ozanimod.